Cover Story
Free
By Matthew Bin Han Ong
The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI's National Clinical Trials Network and the NCI Community Oncology Research Program.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- NCI paylines to drop to 9th percentile amid CRs and uncertainty
- Brian Druker steps down as CEO of OHSU Knight Cancer Center
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - An NCI initiative focuses on early-onset cancers
- An elephant in the room: Grief in young adults with cancer
- Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities